Back to Search
Start Over
Nektar Therapeutics Announces NKTR-255 Following CD19-directed CAR-T Therapy Enhanced Complete Response Rates in Patients with Relapsed or Refractory Large B-cell Lymphoma at the 66th Annual ASH Meeting
- Source :
- ENP Newswire. December 9, 2024
- Publication Year :
- 2024
-
Abstract
- ENPNewswire-December 9, 2024--Nektar Therapeutics Announces NKTR-255 Following CD19-directed CAR-T Therapy Enhanced Complete Response Rates in Patients with Relapsed or Refractory Large B-cell Lymphoma at the 66th Annual ASH Meeting (C)2024 [...]
- Subjects :
- Nektar Therapeutics
Subjects
Details
- Language :
- English
- Database :
- Gale General OneFile
- Journal :
- ENP Newswire
- Publication Type :
- News
- Accession number :
- edsgcl.819367962